MOS Prebiotic for Gut Health in Healthy Older Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how mannooligosaccharides (MOS), a substance derived from baker's yeast, might improve gut health in older adults. Researchers aim to determine if MOS can aid digestion and positively alter gut bacteria. The trial seeks adults aged 50 to 99 who are generally healthy or have been diagnosed with Parkinson's or multiple system atrophy. Participants must not have a yeast allergy, kidney disease, or a history of intestinal diseases or surgeries. As an unphased trial, this study offers participants the chance to contribute to groundbreaking research on improving gut health.
Will I have to stop taking my current medications?
The trial requires that you stop using antibiotics, laxatives, and antidiarrheal medications before participating. If you are using any of these, you will need to stop them to be eligible for the study.
What prior data suggests that Mannooligosaccharides are safe for older adults?
Research has shown that mannooligosaccharides (MOS), derived from baker's yeast, are generally safe and well-tolerated. Studies have found that MOS can improve gut health, positively affecting the stomach and intestines without causing harm.
While specific human safety data is lacking, MOS are under study for their benefits in animal nutrition, suggesting they are safe for consumption. Additionally, similar oligosaccharides in human milk play a crucial role in infant gut health, supporting their safety.
The study is in a "Not Applicable" phase, indicating that the treatment is likely considered safe enough to test its effects rather than its safety. Overall, current evidence suggests MOS are safe to use.12345Why are researchers excited about this trial?
Researchers are excited about mannooligosaccharides for gut health in older adults because it offers a novel approach by using a prebiotic derived from yeast extract. Unlike typical probiotics that introduce live bacteria into the gut, mannooligosaccharides serve as a food source for the beneficial bacteria already present, potentially boosting their growth and activity naturally. This mechanism may lead to improved gut health without the need for introducing foreign bacteria, making it a promising option for supporting the microbiome in a more gentle and body-friendly manner.
What evidence suggests that Mannooligosaccharides might be an effective treatment for gut health?
Research shows that Mannooligosaccharides (MOS), the treatment under study in this trial, can improve gut health. Studies have found that MOS positively affects the gut microbiota, the tiny organisms living in the gut. This change promotes healthier intestines. MOS also reduces swelling and irritation in the gut due to its anti-inflammatory effects. These findings suggest that MOS might enhance digestive function and alleviate symptoms in older adults.12678
Are You a Good Fit for This Trial?
This trial is for healthy older adults aged 60-99 who can consent in English and are willing to follow the study procedures. It's not suitable for those with kidney disease, gastrointestinal surgeries or conditions, yeast allergies, current cancer treatment, recent antibiotic use, or if they're taking certain medications like laxatives.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 15 g per day of yeast-derived mannooligosaccharides to evaluate effects on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Mannooligosaccharides
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Lallemand Bio-Ingredients
Collaborator